Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_3
1
17%
Ph phase_2
1
17%
Ph not_applicable
2
33%
Ph phase_4
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting2
Completed2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A2 (33.3%)

Trials by Status

recruiting233%
completed233%
not_yet_recruiting233%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
DRUG
Total Trials
6